Alzamend Neuro (ALZN) News Today → Three basic steps to building the Ultimate Dividend Portfolio. (From DTI) (Ad) Free ALZN Stock Alerts $0.64 +0.01 (+1.03%) (As of 01:23 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12, 2024 | americanbankingnews.comShort Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 55.2%May 9, 2024 | finance.yahoo.comAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionMay 9, 2024 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred SharesMay 7, 2024 | msn.comAlzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares SlideMay 7, 2024 | finance.yahoo.comAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramApril 24, 2024 | msn.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingApril 17, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42March 26, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024February 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 13, 2024 | realmoney.thestreet.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 3, 2024 | msn.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyDecember 19, 2023 | markets.businessinsider.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 11, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsDecember 11, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next YearNovember 20, 2023 | marketwatch.comAlzamend Neuro Gets FDA Approval for Trial of Depression TreatmentNovember 20, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder StudyNovember 20, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNovember 16, 2023 | finance.yahoo.comAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNovember 13, 2023 | msn.comEXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug CandidateNovember 13, 2023 | finance.yahoo.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001November 2, 2023 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 1306.25% to 57.38October 30, 2023 | benzinga.comWhy Alzamend Neuro (ALZN) Stock Is Nosediving TodayOctober 30, 2023 | finance.yahoo.comAlzamend Neuro Announces Reverse Stock SplitOctober 25, 2023 | finance.yahoo.comAlzamend Neuro, Inc. (9ZT0.F)October 23, 2023 | businesswire.comAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001October 2, 2023 | msn.comEXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar DisorderOctober 2, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsSeptember 27, 2023 | seekingalpha.comAlzamend Neuro CFO Katzoff buys 53K sharesSeptember 26, 2023 | yahoo.comRep. Jennifer Wexton Will Not Run for Re-Election After Rare Neurological Disorder DiagnosisSeptember 22, 2023 | finance.yahoo.comAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementAugust 30, 2023 | msn.comEXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar DisorderAugust 30, 2023 | finance.yahoo.comAlzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsAugust 25, 2023 | benzinga.comBenzinga NeuroAugust 24, 2023 | finance.yahoo.comWe're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn RateJune 28, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)June 24, 2023 | morningstar.comAlzamend Neuro Inc Ordinary SharesJune 22, 2023 | finance.yahoo.comAlzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001June 22, 2023 | benzinga.comEXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's StudyJune 13, 2023 | finance.yahoo.comAlzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare ConferenceApril 14, 2023 | benzinga.comAlzamend Neuro Stock (NASDAQ:ALZN), DividendsApril 12, 2023 | msn.comMaxim Group Initiates Coverage of Alzamend Neuro (ALZN) with Buy RecommendationApril 3, 2023 | finance.yahoo.comAlzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeApril 3, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy VaccineApril 3, 2023 | finance.yahoo.comKILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s TypeMarch 22, 2023 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's TrialMarch 17, 2023 | finance.yahoo.comWe Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth CarefullyMarch 16, 2023 | finance.yahoo.comAlzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business UpdateFebruary 21, 2023 | barrons.comAlzamend Neuro Inc. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. ALZN Media Mentions By Week ALZN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALZN News Sentiment▼0.000.43▲Average Medical News Sentiment ALZN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALZN Articles This Week▼00▲ALZN Articles Average Week Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cyclacel Pharmaceuticals News Today Petros Pharmaceuticals News Today Exicure News Today Ensysce Biosciences News Today Soligenix News Today Tharimmune News Today Clever Leaves News Today GT Biopharma News Today Seelos Therapeutics News Today ZyVersa Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALZN) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport Society[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.